These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2133276)

  • 1. Tumor necrosis factor (TNF) and endotoxin prime effects of PAF in vivo.
    Heuer HO; Letts G; Meade CJ
    J Lipid Mediat; 1990; 2 Suppl():S101-8. PubMed ID: 2133276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a new and specific PAF-antagonist, WEB 2086, on PAF and endotoxin/tumor necrosis factor induced changes in mortality and intestinal transit velocity.
    Heuer H
    Prog Clin Biol Res; 1989; 308():919-24. PubMed ID: 2780739
    [No Abstract]   [Full Text] [Related]  

  • 3. Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees.
    Kuipers B; van der Poll T; Levi M; van Deventer SJ; ten Cate H; Imai Y; Hack CE; ten Cate JW
    J Immunol; 1994 Mar; 152(5):2438-46. PubMed ID: 8133055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endotoxin-induced pulmonary leukostasis in the rat: role of platelet-activating factor and tumor necrosis factor.
    Chang SW
    J Lab Clin Med; 1994 Jan; 123(1):65-72. PubMed ID: 8288963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet activating factor (PAF) and tumor necrosis factor-alpha (TNF alpha) interactions in endotoxemic shock: studies with BN 50739, a novel PAF antagonist.
    Rabinovici R; Yue TL; Farhat M; Smith EF; Esser KM; Slivjak M; Feuerstein G
    J Pharmacol Exp Ther; 1990 Oct; 255(1):256-63. PubMed ID: 2213560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of in vivo 'priming' on endotoxin-induced hypotension and tissue injury. The role of PAF and tumor necrosis factor.
    Sun XM; Hsueh W; Torre-Amione G
    Am J Pathol; 1990 Apr; 136(4):949-56. PubMed ID: 2327475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
    Heuer HO; Casals-Stenzel J; Muacevic G; Weber KH
    J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effect of BN 50739, a new platelet-activating factor antagonist, in endotoxin-treated rabbits.
    Yue TL; Farhat M; Rabinovici R; Perera PY; Vogel SN; Feuerstein G
    J Pharmacol Exp Ther; 1990 Sep; 254(3):976-81. PubMed ID: 2395125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
    Herbert JM; Fraisse L; Bachy A; Valette G; Savi P; Laplace MC; Lassalle J; Roche B; Lale A; Keane PE
    J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
    Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
    J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitric oxide mediates angiogenesis induced in vivo by platelet-activating factor and tumor necrosis factor-alpha.
    Montrucchio G; Lupia E; de Martino A; Battaglia E; Arese M; Tizzani A; Bussolino F; Camussi G
    Am J Pathol; 1997 Aug; 151(2):557-63. PubMed ID: 9250168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet-activating factor antagonists suppress the generation of tumor necrosis factor-alpha and superoxide induced by lipopolysaccharide or phorbol ester in rat liver macrophages.
    Zhang F; Decker K
    Eur Cytokine Netw; 1994; 5(3):311-7. PubMed ID: 7948767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet-activating factor antagonists in experimental shock.
    Muacevic G; Heuer HO
    Arzneimittelforschung; 1992 Aug; 42(8):1001-4. PubMed ID: 1418068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet-activating factor produces shock, in vivo complement activation, and tissue injury in mice.
    Sun XM; Hsueh W
    J Immunol; 1991 Jul; 147(2):509-14. PubMed ID: 2071893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of platelet activating factor to hemodynamic and sympathetic responses to bacterial endotoxin in conscious rats.
    Qi M; Jones SB
    Circ Shock; 1990 Oct; 32(2):153-63. PubMed ID: 2253318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological actions of PCA 4248, a new platelet-activating factor receptor antagonist: in vivo studies.
    Fernández-Gallardo S; Ortega MP; Priego JG; de Casa-Juana MF; Sunkel C; Sánchez Crespo M
    J Pharmacol Exp Ther; 1990 Oct; 255(1):34-9. PubMed ID: 2170626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of tumor metastasis by platelet-activating factor.
    Im SY; Ko HM; Kim JW; Lee HK; Ha TY; Lee HB; Oh SJ; Bai S; Chung KC; Lee YB; Kang HS; Chun SB
    Cancer Res; 1996 Jun; 56(11):2662-5. PubMed ID: 8653713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet-activating factor is a mediator in tumor necrosis factor/galactosamine-induced lethality.
    Libert C; Van Molle W; Brouckaert P; Fiers W
    J Inflamm; 1995-1996; 46(3):139-43. PubMed ID: 8844494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of platelet activating factor antagonist WEB 2086 on the production of TNF from murine peritoneal macrophages.
    Ju DW; Zheng QY; Wang HB; Wang XF; Fang J
    Yao Xue Xue Bao; 1993; 28(10):721-7. PubMed ID: 8009983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pathophysiological role of PAF in anaphylactic lung reaction in the guinea pig and in endotoxin shock evidenced by the specific PAF-antagonist WEB 2086.
    Heuer H; Casals-Stenzel J
    Prog Clin Biol Res; 1989; 308():925-30. PubMed ID: 2675077
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.